Evidence map›Paper›PMID 25773687›Full record

ArticleArchives of Iranian medicine2015

Cardiovascular disease mortality and years of life lost attributable to non-optimal systolic blood pressure and hypertension in northeastern Iran.

Sadaf G Sepanlou, Roger B Newson, Hossein Poustchi, Masoud M Malekzadeh, Parisa Rezanejad Asl, Arash Etemadi, Hooman Khademi, Farhad Islami, Akram Pourshams, Paul D Pharoah and 6 more

Open access · greenAbstract read
In one paragraph

Article in Archives of Iranian medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 4 countries.

Sadaf G SepanlouDigestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. dr.reza.malekzadeh@gmail.com, malek@ams.ac.ir.
Roger B NewsonNational Heart and Lung Institute, Imperial College London, UK.
Hossein PoustchiDigestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Masoud M MalekzadehDigestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Parisa Rezanejad AslDigestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Arash EtemadiDigestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Hooman KhademiDigestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran, International Agency for Research on Cancer, Lyon, France.
Farhad IslamiDigestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran, Surveillance and Health Services Research, American Cancer Society, Atlanta, USA.
Akram PourshamsDigestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Paul D PharoahDepartments of Oncology and Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Christian C AbnetDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Paul BrennanInternational Agency for Research on Cancer, Lyon, France.
Paolo BofettaThe Tisch Cancer Institute, and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sanford M DawseyDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Farin KamangarDigestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran, Department of Public Health Analysis, School of Community Health and Policy, Morgan State University, Baltimore, USA.
Reza MalekzadehDigestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRDivision of Cancer Epidemiology and GeneticsShariati Hospital · IRCentre International de Recherche sur le Cancer · FRIcahn School of Medicine at Mount Sinai · USImperial College London · GBUniversity of Cambridge · GB

Funding

Upper Gastrointestinal Cancer StudiesZIACP000185 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ABNET, CHRISTIAN · 2009 to 2025
$25.6M
Cancer Research UKIntramural NIH HHS ZIA CP000185World Health Organization 001
6 · The paper itself

Abstract

backgroundHigh blood pressure is the second most important risk factor of cardiovascular diseases (CVDs) in Iran. It is imperative to estimate the burden of CVDs that can be averted if high blood pressure is controlled at the population level. The aim of the current study was to estimate the avertable CVD mortality in the setting of Golestan Cohort Study (GCS).

methodsOver 50,000 participants were recruited and followed for a median of 7 years. The exposures of interest in this study were non-optimal systolic blood pressure (SBP) and hypertension measured at baseline. Deaths by cause have been precisely recorded. The Population Attributable Fraction (PAF) of deaths and Years of Life Lost (YLLs) due to CVDs attributable to exposures of interest were calculated.

resultsOverall, 223 deaths due to ischemic heart disease (IHD), 207 deaths due to cerebrovascular accidents (CVA), and 460 deaths due to all CVDs could be averted if the SBP of all subjects in the study were optimal. Similarly, 5,560 YLLs due to IHD, 4,771 YLLs due to CVA, and 11,135 YLLs due to CVDs could be prevented if SBP were optimal. In all age groups, the avertable deaths and YLLs were higher due to IHD compared with CVA. Deaths and YLLs attributable to non-optimal SBP in women were less than men.

conclusionsA very large proportion of CVD deaths can be averted if blood pressure is controlled in Iran. Effective interventions in primary and secondary health care setting are mandatory to be implemented as early as possible.

Indexed as

SystoleAdultAgedAged, 80 and overCardiovascular DiseasesFemaleHumansHypertensionMaleMiddle Aged

Identifiers

PMID25773687
PMCPMC5784772
OpenAlexW2404743181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.